Latest News
60 Degrees Pharmaceuticals, Inc.
- Form 8K 60 Degrees Pharmaceuticals Inc For: 23 October By Investing.com
- 60 Degrees Pharmaceuticals Outlines Tafenoquine Progress and Potential 2027 FDA Filing
- A 30-patient trial remains blinded as 60 Degrees Pharma (SXTP) plans its next FDA meeting.
- 60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- 60 Degrees highlights interim tafenoquine data, caps enrollment
- 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized
- 60 Degrees Pharmaceuticals Shares Rise 12.5% Premarket - 60 Degrees (NASDAQ:SXTP)
- D.C.-Based 60 Degrees Pharmaceuticals Sets January 2027 Readout for Babesiosis Study, Plans FDA Pre-sNDA Meeting
- 60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- 60 Degrees Pharma Nears Key Tafenoquine Data Readout In Babesiosis
Headlines from the last 30 days, linking to the original publishers. See all market news →